Communiqués Calliditas Therapeutics AB Nasdaq

Actions

CALT

US13124Q1067

Temps Différé Nasdaq Autres places de cotation 17:04:24 14/06/2024			Varia. 5j.	Varia. 1 janv.
38,84 ^USD	-0,59 %		-1,65 %	+50,87 %

07/06	Les actions européennes négociées aux États-Unis et les American Depositary Receipts en baisse dans les échanges de vendredi	MT
06/06	Les entreprises technologiques sont en tête des actions européennes négociées aux États-Unis, les American Depositary Receipts étant en hausse jeudi.	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy	30/05	AQ
CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders	28/05	BU
Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress	28/05	AQ
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation	28/05	AQ
Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Presentation)	23/05	PU
Calliditas Therapeutics : May 23, 2024 Interim Report Q1 2024 (Report)	23/05	PU
Calliditas Q1 report, January - March 2024	23/05	AQ
In Person & Virtual R&D Day: The Anti Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action	16/05	PU
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action	16/05	AQ
Calliditas Therapeutics : Invitation to the presentation of Calliditas´s interim report January - March 2024	16/05	PU
Invitation to the presentation of Calliditas's interim report January - March 2024	16/05	AQ
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm	15/05	AQ
Notice of annual general meeting of Calliditas Therapeutics AB (publ)	15/05	AQ
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China	14/05	AQ
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib	06/05	AQ
Calliditas Therapeutics' 2023 Annual Report Published	24/04	AQ
Calliditas Announces Positive NefIgArd Open Label Extension Results	24/04	AQ
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	18/04	AQ
Calliditas Therapeutics to Attend Conferences in April	09/04	AQ
Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires	08/04	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Calliditas Therapeutics AB Nasdaq

Actions

CALT

US13124Q1067

Communiqués

Filtres